非顺铂一线治疗转移性尿路上皮癌的疗效比较:2期IMvigor210研究与美国退伍军人健康管理局治疗患者的对比
本研究比较了2期IMvigor210试验中接受阿替利珠单抗治疗的顺铂不耐受转移性尿路上皮癌患者与美国退伍军人健康管理局(VHA)中接受卡铂为基础化疗的患者。经熵平衡加权后,阿替利珠单抗组中位总生存期为15.0个月,任何卡铂方案组为12.1个月,卡铂-吉西他滨组为8.7个月;阿替利珠单抗在9个月后对比任何卡铂方案(HR 0.43;p=0.004)、在5个月后对比卡铂-吉西他滨(HR 0.52;p=0.005)显示总生存获益。作者认为一线阿替利珠单抗可能提供总生存获益。
要点
- 阿替利珠单抗组中位OS 15.0个月,任何卡铂方案组12.1个月,卡铂-吉西他滨组8.7个月。
- 阿替利珠单抗对比任何卡铂方案9个月后HR 0.43(p=0.004)。
- 阿替利珠单抗对比卡铂-吉西他滨5个月后HR 0.52(p=0.005)。
核心结论
- 顺铂不耐受转移性尿路上皮癌一线阿替利珠单抗对比卡铂为基础治疗,可能在5-9个月后提供总生存获益,取决于方案。
研究设计与样本
- 2期IMvigor210试验(ClinicalTrials.gov NCT02951767)队列1中接受阿替利珠单抗治疗的顺铂不耐受转移性尿路上皮癌患者,对比VHA医疗系统(2006-2017年)中按常规临床实践治疗、并应用替代指标复现IMvigor210入排标准的患者。
- 采用熵平衡加权平衡预设基线特征,以加权Kaplan-Meier和Cox方法分析总生存期。
主要发现
- 阿替利珠单抗组(n=110)中位OS为15.0个月,任何卡铂为基础化疗组(n=282)为12.1个月,卡铂-吉西他滨组(n=120)为8.7个月。
- 阿替利珠单抗对比任何卡铂方案在9个月后显示OS获益(HR 0.43;p=0.004)。
- 阿替利珠单抗对比卡铂-吉西他滨在5个月后显示OS获益(HR 0.52;p=0.005)。
关键数值与推荐
- 阿替利珠单抗组中位OS 15.0个月(n=110)。
- 任何卡铂为基础化疗组中位OS 12.1个月(n=282)。
- 卡铂-吉西他滨组中位OS 8.7个月(n=120)。
- 阿替利珠单抗对比任何卡铂方案9个月后HR 0.43;p=0.004。
- 阿替利珠单抗对比卡铂-吉西他滨5个月后HR 0.52;p=0.005。
临床怎么用
- 作者认为,顺铂不耐受转移性尿路上皮癌一线阿替利珠单抗对比卡铂为基础治疗可能在5-9个月后提供总生存获益,取决于方案。
局限性
- VHA队列以男性为主。
- 随访≤24个月。
- 非随机研究存在混杂调整的潜在局限性,VHA数据中临床测量的可及性限制了混杂调整,但允许在VHA队列中复现IMvigor210的排除标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First-line treatments for cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such as atezolizumab (anti-PD-L1). OBJECTIVE: To compare overall survival (OS) among patients with mUC treated in the first-line setting with atezolizumab versus carboplatin-based chemotherapies (any carboplatin-based regimens or carboplatin-gemcitabine). DESIGN, SETTING, AND PARTICIPANTS: Cisplatin-ineligible patients with mUC from the phase 2 trial IMvigor210 (ClinicalTrials.gov NCT02951767) treated with atezolizumab and patients from the Veterans Health Administration (VHA) health care system (2006-2017, with IMvigor210 eligibility criteria applied using proxy measurements) treated according to normal clinical practice. INTERVENTIONS: IMvigor210 cohort 1 patients were treated with atezolizumab, and real-world VHA cohorts were treated with carboplatin-based regimens. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Entropy-balance weighting was applied to balance prespecified baseline patient characteristics. OS was analyzed using weighted Kaplan-Meier and Cox methods. RESULTS AND LIMITATIONS: The median OS was 15.0 mo with atezolizumab (n = 110), 12.1 mo with any carboplatin-based chemotherapy (n = 282), and 8.7 mo with carboplatin-gemcitabine (n = 120). An OS benefit occurred with atezolizumab versus carboplatin-based regimens after 9 mo (hazard ratio [HR] 0.43; p = 0.004) and with atezolizumab versus carboplatin-gemcitabine after 5 mo (HR 0.52; p = 0.005). Study limitations include a predominantly male VHA cohort and ≤24-mo follow-up. Adjustment for confounding, a potential limitation of nonrandomized studies, was limited by the availability of clinical measurements in the VHA data, which allowed for replication of IMvigor210 exclusions in the VHA cohorts. CONCLUSIONS: First-line atezolizumab for cisplatin-ineligible mUC may provide an OS benefit over carboplatin-based treatments after 5-9 mo, depending on the regimen. PATIENT SUMMARY: Many patients with metastatic urothelial carcinoma are ineligible for cisplatin-based chemotherapy. This study compared patients from a clinical trial receiving the immunotherapeutic agent atezolizumab with those in Veterans Health Administration clinical practice receiving carboplatin-based chemotherapy. Atezolizumab provided a survival benefit over chemotherapy after 5-9 mo.
引用
- Vander Velde N, Guerin A, Ionescu-Ittu R, et al. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. Eur Urol Oncol. 2018. PMID: 30929841. doi:10.1016/j.euo.2018.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。